Abstract
Hepatitis B virus (HBV) reactivation is a well-recognized complication in patients with chronic HBV infection receiving cytotoxic or immunosuppressive chemotherapy. Imatinib mesylate and nilotinib are selective Bcr/Abl tyrosine kinase inhibitors, which are now widely used in the treatment of patients with chronic myeloid leukemia. Although HBV reactivation induced by imatinib mesylate has been reported, nilotinib-related HBV reactivation has not been reported in the English literature. We report here 2 cases of HBV reactivation in chronic myeloid leukemia patients receiving imatinib mesylate and a novel case of nilotinib related HBV reactivation.
Keywords:
Chronic myeloid leukemia; Hepatitis B virus; Imatinib mesylate; Nilotinib; Tyrosine kinase inhibitor.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / adverse effects*
-
Antiviral Agents / therapeutic use
-
Benzamides / adverse effects
-
Female
-
Hepatitis B virus / drug effects*
-
Hepatitis B virus / physiology
-
Hepatitis B, Chronic / complications*
-
Hepatitis B, Chronic / diagnosis
-
Hepatitis B, Chronic / drug therapy
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
-
Male
-
Middle Aged
-
Piperazines / adverse effects
-
Protein Kinase Inhibitors / adverse effects*
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Protein-Tyrosine Kinases / metabolism
-
Pyrimidines / adverse effects
-
Time Factors
-
Treatment Outcome
-
Virus Activation / drug effects*
Substances
-
Antineoplastic Agents
-
Antiviral Agents
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Imatinib Mesylate
-
Protein-Tyrosine Kinases
-
nilotinib